T. Rowe Price Associates’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $40.5M | Buy |
|
|||||
|
2025
Q1 | $22.8M | Buy |
|
|||||
|
2024
Q4 | $25.4M | Buy |
|
|||||
|
2024
Q3 | $1.02M | Buy |
|
|||||
|
2024
Q2 | $578K | Buy |
|
|||||
|
2024
Q1 | $550K | Buy |
|
|||||
|
2023
Q4 | $565K | Sell |
|
|||||
|
2023
Q3 | $407K | Buy |
|
|||||
|
2023
Q2 | $570K | Buy |
|
|||||
|
2023
Q1 | $577K | Sell |
|
|||||
|
2022
Q4 | $727K | Buy |
|
|||||
|
2022
Q3 | $361K | Buy |
|